S2-E60 - Explore Major Upcoming Events and Issues for NAFLD and NASH At Our NASH-TAG 2022 Preview

Send us Fan MailNASH-TAG 2022 Co-chair Stephen Harrison and Steering Committee Member Jörn Schattenberg review the upcoming conference, focusing on major issues in NAFLD and NASH diagnosis, staging, treatment and monitoring.NASH-TAG 2022 faculty, format and schedule suggest that this conference will produce breakthroughs in knowledge and consensus about NAFLD therapy. This week, NASH-TAG 2022 Steering Committee member Jörn Schattenberg joins the Surfers to discuss key presentations and critical issues in the conference. NASH-TAG co-chair Stephen Harrison walks the panel and audience through the entire NASH-TAG agenda, with Jörn, Louise Campbell and Roger Green contributing questions and comments throughout the session.Highlights from the program:8:54 – Stephen provides a little background on NASH-TAG9:44 – Stephen begins to discuss Friday morning program10:34 – Describing the first session, “A one-stop shop”13:10 – Jörn Schattenberg comments on Session One14:09 – Roger Green comments on Session One15:10 – Louise Campbell comments on Session One15:26 – Stephen discusses Sessions Two and Three, with comments on the oral presentations thrown in18:24 – Louise comments specifically on the talk about why NASH-related HCC is resistant to treatment; Stephen agrees and amplifies19:02 – Jörn comments on Sessions Two and Three20:19 – Stephen discusses the break session and goes on to discuss Session Four23:18 – Roger asks about which oral presentations will appear at the conference, Stephen demurs23:55 – Jörn expresses enthusiasm that the LITMUS, NIMBLE and the NIH Cirrhosis Network25:15 – Stephen discusses Session 5 26:43 – Roger expresses enthusiasm for the entire afternoon program (Sessions 4 and 5)27:09 – Stephen discusses the scope and scale of the efforts LITMUS and NIMBLE are making, and goes on to discuss recent progress against cirrhosis in the context of mentioning the cirrhosis network28:29 – Jörn expresses positive outlook on the Path AI and HistoIndex presentations29:05 – Stephen begins review of Day Two, Session Six.]31:14 – Stephen: “This may be one of the most intriguing sessions”32:25 – Roger begins comments on Session Six33:02 – Louise comments on Session Six35:07 – Stephen begins review of Session Seven36:24 – Louise begins comments on Session Seven37:06 – Stephen begins discussion of the second evening with Session Seven37:56 – Jörn comments on Session Seven38:22 – Stephen discusses the last two hours of the meetings – “fireside chats” with governmental, corporate and academic stakeholders about whether it is time to pivot away from semi-quantitative biopsy-based endpoints toward NITs.40:04 – Roger agrees with Stephen’s exceptional excitement about the potential of the fireside chats; Stephen elaborates on what will make the chats so special42:23 – Final question: one more thing each panelist would like to point out in the agenda?42:34 – Jörn praises “great program,” wonders whether the fireside chats should have included a patient representative43:04 – Louise echoes Jörn’s comments on program quality and wish for a patient representative in the fireside chats43:50 – Roger asks whether talks on the PNPLA3 and HSD17B13 knockdowns presage a longer-term future for therapies44:42 – Stephen is partial to the fireside chats, expresses belief that researchers will take away from this meeting something they can use in research454:52 – Business section